Eric Schmid

Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics, a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.

Cooley advised Hughes & Company, a private equity firm focused on healthcare software and technology-enabled services, on its strategic investment in Health Data Innovations, a founder-owned healthcare data integration-as-a-service company.

Cooley advised M33 Growth, a venture and growth-stage investment firm, on a series of strategic investments in:

• Operix (formerly IFS Core), a provider of software solutions for specialty contractors that allow for more efficient management of field operations personnel and processes through seamless integrations with core accounting platforms.
• PerformLine, a provider of a cloud-based, multichannel sales and marketing compliance platform for the banking, mortgage, insurance and financial services industries to monitor enterprise communication channels for regulatory and brand compliance and improve reporting and issue remediation workflows.
• Leading2Lean, a provider of a cloud-based digital workflow platform for discrete manufacturers that enables factories to implement more efficient production and maintenance processes.
• Yapi, a provider of a communication and patient engagement platform for dental offices that streamlines front office and marketing workflows, automates appointment reminders and digitizes paper-based forms such as patient consents.

Cooley advised Vendr on its $60 million Series A financing round. Partner Harley Brown led the Cooley team advising Vendr, a developer of a SaaS buying platform that enables the world’s fastest-growing companies to purchase SaaS, without friction and at a fair price.